Refine
Has Fulltext
- yes (41)
Is part of the Bibliography
- yes (41)
Year of publication
Document Type
- Doctoral Thesis (41) (remove)
Language
- English (41) (remove)
Keywords
- T-Lymphozyt (5)
- Dendritische Zelle (4)
- HIV (4)
- Immunologie (3)
- Immunreaktion (3)
- Maus (3)
- Ratte (3)
- T cell (3)
- Toleranz (3)
- Antigen CD8 (2)
Institute
- Institut für Virologie und Immunbiologie (41) (remove)
Sonstige beteiligte Institutionen
A CD8+ cell-mediated host defense relies on cognate killing of infected target cells and on local inflammation induced by the secretion of IFN-g. Using assays of single cell resolution, it was studied to what extent these two effector function of CD8+ cells are linked. Granzyme B (GzB) is stored in cytolytic granules of CD8+ cells and its secretion is induced by antigen recognition of these cells. Following entry into the cytosol GzB induces apoptosis in the target cells. It was measured whether GzB release by individual CD8+ cells is accompanied by the secretion of IFN-gƒnƒnand of other cytokines. HIV peptide libraries were tested on bulk peripheral blood mononuclear cells and on purified CD4+ and CD8+ cells obtained from HIV infected individuals. The library included a panel of previously defined HLA class I restricted HIV peptides and an overlapping 20-mer peptide-series that covered the entire gp120 molecule. To characterize the in vivo differentiation state of the T-cells, freshly isolated lymphocytes were tested in assays of 24h duration. The data showed that only ~20% of the peptides triggered the release of both GzB and IFN-g from CD8+ cells. The majority of the HIV peptides induced either GzB or IFN-g, ~40% in each category. The GzB positive, IFN-g negative CD8+ cells did not produce IL-4 or IL-5, which suggests that they do not correspond to Tc2 cells but represent a novel Tc1 subclass, which was termed Tc1c. Also the IFN-g positive, GzB negative CD8+ cell subpopulation represents a yet undefined CD8+ effector cell lineage that was termed Tc1b. Tc1b and Tc1c cells are likely to make different, possibly antagonistic contributions to the control of HIV infection. Since IFN-g activates HIV replication in latently infected macrophages, the secretion of this cytokine by Tc1b cells in the absence of killing may have adverse effects on the host defense. In contrast, cytolysis by Tc1c cells in the absence of IFN-g production might represent the protective class of response. Further studies in the field of Tc1 effector cell diversity should lead to valuable insights for management of infections and developing rationales for vaccine design.
Identification of rat NKT cells and molecular analysis of their surface receptor mediated activation
(2004)
Summary: Originally, NKT cells have been defined by their expression of T-cell receptor (TCR) and NK cell markers NKRP1A in human and NK1.1 (NKRP1C) in mouse. Most of these cells express CD1d-restricted TCR with a characteristic rearrangement- Va24JaQ/Vb11 in human and Va14Ja18/Vb8.2 in mouse, and have been implicated in playing an important role in first line defence and immunoregulation. The subject of this thesis was the characterisation of the hypothetical rat NKT cell population. In the mouse system, CD1d-restricted NK1.1+ T cells represented around 30% of intrahepatic and around 3% of splenic lymphocytes and could be visualised by staining with a-GalCer-loaded mouse CD1d tetramer. Rat NKRP1A+TCR+ cells, similar to mouse NKT cells, were predominantly expressed in the liver. However, their frequency was around 5 fold lower than the frequency of mouse intrahepatic lymphocytes. F344 rat NKT cells, in contrast to mouse CD4+ or DN NK1.1+ T lymphocytes, were of CD8 rather than CD4 phenotype, and did not bind to mCD1d-a-GalCer-tetramer. Since human hepatic CD1d-restricted Va24JQ+ T cells are not as frequent as their mouse counterparts and may express CD8- a marker not expressed by mouse CD1d-restricted cells, it is possible that the phenotype of F344 rat NKT cells corresponds more to the phenotype of human than mouse NKT cells. Similar to mouse NKT cells, F344 rat liver- and spleen-derived lymphocytes were able to produce IL-4 and IFN-g; when stimulated with the synthetic ligand a-GalCer in vitro. Therefore, the lack of binding of rat lymphocytes to mouse CD1d tetramer could not be due to their inability to respond to a-GalCer. To better characterise the reactivity of rat NKRP1A+TCR+ cells to a-GalCer, the rat invariant TCR was analysed. RT-PCR of liver lymphocytes with Va14-specific primers and subsequent cloning revealed a much weaker PCR signal for rat lymphocyte cDNA than for mouse cDNA. Furthermore the analysis of rat AV14JA18 sequences showed that the rat Va14+TCR invariant could be rearranged not only with AJ18 but also with other AJ segments. The low number of clones with in frame Va14Ja18 rearrangement could suggest that only a small proportion of liver lymphocytes were CD1d restricted NKT cells. Mouse and human NKT cells are able to recognise a-GalCer presented by the CD1d-b2 microglobulin complex, leading to their activation, proliferation and cytokine secretion. In order to compare the capacity of mouse and rat CD1d to present a-GalCer, rat CD1d was cloned. Sequence analysis and functional tests in vitro confirmed the structural and functional homology of rat CD1d with mouse CD1d. In parallel, to characterise the reactivity of rat NKRP1A+TCR+ cells to a-GalCer, rat Va14+TCR invariant was cloned and expressed in the TCR- T cell hybridoma BWr/mCD28. Rat Va14TCR+CD28+ transgenic cells secreted IL-2 upon aTCR/CD3 antibody stimulation, but were not specific for a-GalCer. Such cells were also negative in staining with mCD1d-a-GalCer tetramer. The lack of reactivity to a-GalCer and the lack of binding to mouse tetramer were probably caused by amino acid alterations, particularly at position 72 (51 according to IMTG nomenclature) of cloned rat TCRinv. Reversal of these “alterations” using molecular biology techniques was performed but the expression of this TCR on the surface of BWr/mCD28 cells could not be achieved. In contrast to rat TCRinv, mouse Va14+TCR was fully functional and was specific for mouse CD1d tetramer. KT12 hybridoma and BWr/mCD28 cells expressing mouse TCRinv, when stimulated with a-GalCer presented by primary CD1d+ cells or rCD1d transgenic cell lines, produced IL-2 in an Ag- and CD1d-dependent manner. Transgenic lines expressing TCR comprising mouse Va14 and rat Vb8.4 responded to a-GalCer presented by rat and mouse CD1d, and bound mCD1 tetramer. By contrast, cell lines expressing TCR comprising mouse Va14 and rat Vb8.2 responded only to a-GalCer presented by rCD1d and bound weakly to mCD1d tetramer. This suggests that germ line encoded regions of the b-chain (CDR2 or CDR4) bind to species-specific determinants of CD1d. The cytokine secretion of the cell lines was inhibited by anti-CD80 mAb, indicating the importance of CD80-CD28 costimulation in their activation. To check whether rat NKT cells may exist in other rat strains, the frequency and functions of NKRP1A+TCR+ in F344 and LEW rat were compared. F344 and LEW, two rat strains expressing different allelic CD1d forms, varied slightly in the level of CD1d expression, as assessed by staining with a newly generated CD1d specific monoclonal antibody. By contrast, these rat strains differed in terms of a-GalCer recognition. NKRP1A+TCR+ cells were less frequent in LEW than in F344 rats, and did not respond to a-GalCer or the analogue OCH in vitro, a result which is of special interest considering the susceptibility of LEW but not F344 rats to experimentally induced organ specific autoimmune diseases. In summary, the rat and mouse CD1d-invariant TCR systems show a high degree of structural and functional homology, but it seems that invariant NKT cells in rat, similar to such cells in human, occur at lower frequency than in mice. TCR transgenic cell line species-specific patterns of CD1d a-GalCer reactivity will provide a valuable tool for the mapping of CD1d/TCR contacts. Also monoclonal antibodies specific for rat and mouse CD1d, generated in this study, provide valuable tools to determine CD1d protein expression in various rat tissues and will help to better characterise functions of CD1d-restricted rat T cells.
The transcriptional repressor-Blimp-1 terminates differentiation of B lymphocytes as well as myeloid cells. Our data show that Blimp-1 is highly expressed in freshly isolated murine primary T lymphocytes, particularly its minor splice variant. Ectopic expression of Blimp-1 by retroviral transduction neither dramatically altered secretion of IFN-ã or IL-4 nor did it induce the ability to suppress as regulatory T cells. However, induction of Blimp-1 resulted in not only a significant reduction in the production of IL-2 but also an inability to proliferate as well as in the reduced viability. These results demonstrate that Blimp-1 might mark end stages of lineage differentiation in T cells.
Summary: In the present work, two important negative regulators of T cell responses in rats were examined. At the molecular level, rat CTLA-4, a receptor important for deactivating T cell responses, was examined for the expression pattern and in vitro functions. For this purpose, anti-rat CTLA-4 mAbs were generated. Consistent with the studies in mice and humans, rat CTLA-4 was detectable only in CD25+CD4+ regulatory T cells in unstimulated rats, and was upregulated in all activated T cells. Cross-linking rat CTLA-4 led to the deactivation of anti-TCR- and anti-CD28 stimulated (costimulation) T cell responses such as reduction in activation marker expression, proliferation, and cytokine IL-2 production. Although T cells stimulated with the superagonistic anti-CD28 antibody alone without TCR engagement also increased their CTLA-4 expression, a delayed kinetics of CTLA-4 upregulation was found in cells stimulated in this way. The physiological relevance of this finding needs further investigation. At the cellular level, rat CD25+CD4+ regulatory T cells were examined here in detail. Using rat anti-CTLA-4 mAbs, the phenotype of CD25+CD4+ regulatory T cells was investigated. Identical to the mouse and human Treg phenotype, rat CD25+CD4+ T cells constitutively expressed CTLA-4, were predominantly CD45RC low, and expressed high level of CD62L (L-selectin). CD25+CD4+ cells proliferated poorly and were unable to produce IL-2 upon engagement of the TCR and CD28. Furthermore, rat CD25+CD4+ cells produced high amounts of anti-inflammatory cytokine IL-10 upon stimulation. Importantly, freshly isolated CD25+CD4+ T cells from naïve rats exhibited suppressor activities in the in vitro suppressor assays. In vitro, CD25+CD4+ regulatory T cells proliferated vigorously upon superagonistic anti-CD28 stimulation and became very potent suppressor cells. In vivo, a single injection of CD28 superagonist into rats induced transient accumulation and activation of CD25+CD4+ regulatory T cells. These findings suggest firstly that efficient expansion of CD25+CD4+ cells without losing their suppressive effects (even enhance their suppressive activities) can be achieved with the superagonistic anti- CD28 antibody in vitro. Secondly, the induction of disproportional expansion of CD25+CD4+ cells by a single injection of superagonistic anti-CD28 antibody in vivo implies that superagonistic anti-CD28 antibody may be a promising candidate in treating autoimmune diseases by causing a transient increase of activated CD25+CD4+ T cells and thus tipping ongoing autoimmune responses toward selftolerance.
Protein kinase B (PKB), a serine threonine kinase, is highly involved in the regulation of cellular proliferation and survival. To characterize PKB’s function in lymphocyte development and activation, transgenic (tg) mice that express a membrane targeted constitutively active form of PKBa (myr PKB) in T and B cells were analysed. Thymocytes from myr PKB tg mice showed enhanced proliferation after T cell receptor (TCR) engagement compared to wild type (wt) mice. Astonishingly, myr PKB tg thymocytes were capable to proliferate in response to PMA only and were also less sensitive to inhibition by the calcineurin inhibitors CsA or FK506, which indicates the proliferative response of myr PKB tg T cells is relatively independent of calcium mobilisation and calcineurin activity. In addition, when TCR signalling was inhibited by the MEKinase inhibitor PD98059 or the Srckinase inhibitor PP1 myr PKB tg thymocytes again were more resistant to inhibition. Western blot analysis revealed myr PKB enhances activation of the kinases Lck, Raf and Erk after TCR/CD3 stimulation. Thus, myr PKB renders proliferative responses of thymocytes more sensitive to TCR signals by positive regulation of the Lck-Raf-MEK-Erk signalling pathway. Studies on the cellular location of the tg protein showed myr PKB is located in membrane socalled “lipid rafts”. Furthermore, we found that after TCR/CD3 ligation endogenous cytoplasmic PKB moves into “lipid rafts”, which highlights PKB as a crucial mediator of TCR proximal signalling events. Analysing three different TCR tg model systems for positive and negative selection of immature precursors in the thymus, we found myr PKB promotes positive selection of CD4+ but not CD8+ T cells. This most likely results from PKB’s positive cross-talk on Lck-Raf-Erk signalling, which is known to influence thymocyte selection and CD4/CD8-lineage choice. Furthermore, myr PKB enhances phosphorylation of glycogen synthase kinase 3 (GSK3), a negative regulator of the transcription factor NFAT (nuclear factor of activated T cells) and T cell activation, and of the adapter protein c-Cbl. Concerning negative selection, myr PKB enhanced (OT1 mice), reduced (HY mice) or had no influence (OT2 mice) on negative selection. Thus, myr PKB’s effect on negative selection strongly depends on the model system analysed and this most likely results from differences in TCR affinity/avidity and TCR specificity for MHC. 106 Peripheral CD4+ T cells from myr PKB tg mice showed enhanced production of both Th1 and Th2 cytokines. Furthermore, after TCR/CD3 stimulation in the presence of TGF-b1, wt CD4+ T cells showed a drastic inhibition of proliferation, whereas myr PKB tg CD4+ T cells proliferated even better, i.e. they were resistant to the inhibitory TGF-b1 signals. Expression of myr PKB in B cells leads to reduced Ca2+ flux and proliferation after BCR stimulation, but activation of Lyn, SLP-65, c-Cbl and GSK-3 were enhanced. When we analysed B cell subsets in myr PKB tg mice, a decrease in immature and mature B cells became obvious, whereas cell numbers for marginal zone (MZ) B cells were normal. In aged myr PKB tg mice we detected a very strong reduction of pro/pre and immature B cell populations in the bone marrow, indicating PKB is very important for maintenance of B cell development. Furthermore, myr PKB also lead to a strong reduction of peritoneal B-1 cells. However, expression of NFATc1, which is required for B-1 cell development, was comparable between wt and myr PKB tg B-1 cells. To analyse the effect of myr PKB on immunoglobulin production, mice were immunized with thymus dependent (TD) and independent (TI) antigens. In both cases, B cell responses were strongly elevated in myr PKB tg mice. Finally, RT-PCR analyses of in vitro expanded B cells revealed increased Blimp-1 and Notch3 expression in myr PKB tg B cells, which might be primary candidates involved in their enhanced effector function. In summary, this study clearly shows an important cross-talk between PKB and various critical signalling molecules downstream of the TCR and BCR. Thereby active PKB modulates and regulates the thresholds for thymocyte selection and T cell activation as well as for B cell development and function.
In this project two novel murine autoimmune models were to be established in an attempt to further investigate the nervous system disorders of Multiple Sclerosis and Guillain Barré Syndrome. Previous experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune neuritis (EAN) models have demonstrated that T cells play a major role in these diseases. Which roles CD4 and CD8 T cells specifically have in the initiation, propagation and termination of an autoimmune nervous system disorder remains controversial. To this end two transgenic mice specifically expressing the neo-antigen (Ag) ovalbumin (OVA) in either the central nervous system (CNS) or peripheral nervous system (PNS) were to be generated. The myelin basic protein (MBP) is a major component of the myelin sheath both within the CNS and the PNS. Therefore the MBP promoter was employed for its distinct regulatory elements to facilitate exclusive CNS or PNS OVA expression. The adoptive transfer of OVA specific MHCI restricted (OT-I) and MHCII restricted (OT-II) TCR Tg T cells extended the OVA Tg mouse model by allowing potentially encephalitogenic T cells to be tracked in vivo. Specificity for the target Ag should enable the dynamic role of antigen specific T cells in neuroinflammatory diseases to be revealed in more detail.
To analyze the role of protein kinase B(PKB)on developmental and functional aspects of T cells, we have generated transgenic mouse lines expressing a constitutively active form of PKB (myrPKB) in early stages of T cell development.Peripheral CD4+ T cells from PKB tg mice are hyperreactive, more efficient in producing th1 and th2 cytokines and show faster and CD28 co-stimulation independent cell cycle progression.Interestingly PKB tg T cells are resistant to CsA treatment in proliferation and cytokine production.Further analysis show PKB tg CD4+ T cells have a drastically reduced nuclear translocation of NFAT proteins and this is due to a direct interaction between PKB and NFAT. To study whether the negative regulatiopn of NFATs by PKB affects T cell development, we analyzed double tg mice expressing both, a constitutively active version of calcineurin (dCam) and myrPKB. dCam tg mice have a severe block in thymocyte development at the DN3 stage.But in the dCam/PKB double tg mice this developmental block is significantly rescued.This rescue of thymocyte development by PKB is due to the expression of RAG1 and subsequent TCRb chain expression. CsA treatment of neonatal thymic lobes from dCam mice restores normal thymocyte development, indicating involvement of NFATs in the severe block in dCam thymocyte development.Confocal studies clearly established that compared to dCam DN cells there is a significant reduction in the nuclear levels of NFATc1 and NFATc3 in dCam/PKB cells.Downregulation of nuclear NFAT levels by myrPKB thus seems to be an essential parameter in dCam cells to proceed with normal differentiation. In summary, the data from PKB tg peripheral CD4+ T cells and dCam/PKB double tg thymocytes clearly establish PKB as an important modulator of T cell development and function and PKB as a novel negative regulator of NFAT activation.
Regulation of B lymphocyte terminal differentiation and death by the transcription factor Blimp-1
(2005)
B lymphocyte induced maturation protein-1 (Blimp-1) and X-box-binding protein-1 (XBP-1) are indispensible transcription factors required for B lymphocyte terminal differentiation into Ig secreting plasma cells. Occurrence of an unfolded protein response (UPR) and XBP-1 splicing, due to elevated Ig levels, are critical events during plasma cell generation. However, the upstream molecule sufficient to trigger these events remain elusive. Because ectopic expression of Blimp-1 in B cells is sufficient to generate plasma cells, it is plausible that Blimp-1 might be the upstream molecule, sufficient for the induction of UPR and XBP-1 splicing. The results from the current study indicate that ectopic expression of Blimp-1 or its N-terminal domain, in B cells, is sufficient to induce XBP-1 splicing, UPR and Ig (immunoglobulin) secretion. Further more Blimp-1 is able to directly repress the antiapoptotic gene A1, by binding to specific DNA elements in A1 promoter. This repression of A1 by Blimp-1 seems to be an important prerequisite for Plasma cell differentiation because ectopic expression of A1 in primary B cells resulted in reduced immunoglobulin secretion.
Effects of desialyation on TCR-cross-linking and antigen sensitivity of CD8 positive T lymphocytes
(2005)
The featured experiments focus on changes in T cell membrane glycosylation as a possible means of controlling TCR cross-linking. Taking the long known fact that activated T cells show decreased levels of surface sialic acid as a starting point, differences in ligand binding and cellular reaction upon in vitro stimulation were investigated in naïve, activated and enzymatically desialyated CD8+, 2C TCR transgenic mouse lymphocytes. To detect differences in ligand binding lymphocytes were incubated with various concentrations of fluorescently labeled, soluble MHC/Ig fusion proteins until equilibrium was reached. Without previous washing, cells were analyzed by flow cytometry, determined MCF values were normalized to the plateau and fit to a mathematical model of equilibrium binding of divalent ligands to monomorphic receptors (Perelson 1984). Parameters derived from the model fit of binding data show, that neuraminidase treatment of T cells was sufficient to mimic a partially activated phenotype, showing enhanced TCR cross-linking. Enhanced TCR cross-linking was found to be dependent on the presence of CD8, as neuraminidase treatment of DN cells lead to decreased cross-linking. To elucidate the physiological relevance of desialyation induced increases in TCR cross-linking early tyrosine phosphorylation events and proliferative response upon in vitro stimulation of T cells were investigated. Both were found enhanced in neuraminidase treated cells, as compared to native cells. In conclusion the featured experiments suggest a role of surface sialic acid in controlling TCR cross-linking on naïve and activated T cells.
Glucocorticoids (GCs) are small lipophilic compounds that mediate a plethora of biological effects by binding to the intracellular glucocorticoid receptor (GR) which, in turn, translocates to the nucleus and directly or indirectly regulates gene transcription. GCs remain the cornerstone in the treatment for a number of hematological malignancies, including leukemia, lymphoma and myeloma. Extensive literature suggests that the efficacy of GCs stems from their ability to mediate apoptosis. Despite the enormous strides made in our understanding of regulated cell death, the exact mechanism by which GCs cause apoptosis is still unknown. The data obtained so far provide strong evidence that gene transactivation by the GR underlies the initiation phase of GC-induced thymocyte apoptosis. Furthermore, the multicatalytic proteasome, several members of the Bcl-2 family, changes in calcium flux as well as caspases have been identified as important players in the execution phase of GC-mediated cell death. However, the exact sequence of events in this process still remains elusive. A major problem of the current discussion arises from the fact that different cell types, such as thymocytes, peripheral T cells and lymphoma cells are compared without acknowledging their different characteristics and gene expression profiles. Although it is generally assumed that GCs induce apoptosis via a conserved mechanism, this is not supported by any data. In other words, it is possible that thymocytes, peripheral T cells and lymphoma cells may undergo cell death along different pathways. We therefore wondered whether a unique signal transduction pathway is engaged by GCs to initiate and execute cell death in all types of T lymphocytes or whether distinct pathways exist. Therefore, we compared the role of the proteasome, various caspases, the lysosomal compartment and other factors in GC-induced apoptosis of murine thymocytes and peripheral T cells as well as T-ALL lymphoma cells. Our findings show that the initiation phase of GC-induced apoptosis is similar irrespective of the differentiation state of the cell. Apoptosis in both thymocytes and peripheral T cells is mediated by the GR and depends on gene transcription. In contrast, the execution phase significantly differs between thymocyte and peripheral T cells in its requirement for a number of signal transduction components. Whilst in thymocytes, the proteasome, caspases 3, 8 and 9 as well as cathepsin B play an important role in GC-induced apoptosis, these factors are dispensable for the induction of cell death in peripheral T cells. In contrast, changes in the expression and intracellular location of Bcl-2 family members do not appear to contribute to GC-induced apoptosis in either cell type. Importantly, our observation that GC treatment of thymocytes leads to an activation of the lysosomal protease cathepsin B and that this is an essential step in the induction of cell death by GCs, is the first indication that a lysosomal amplification loop is involved in this process. Analysis of GC-induced apoptosis in several T-ALL cell lines further indicates that the signaling pathway induced by GCs in thymocytes but not in peripheral T cells is shared by all lymphoma cell-types analyzed. Given the therapeutic importance of high-dose GC-therapy for the treatment of hematological malignancies, this finding could potentially form a basis for new anti-cancer strategies in the future, which specifically target tumor cells whilst leaving peripheral T cells of patients untouched.